James C Ballenger

Summary

Publications

  1. ncbi Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety
    James C Ballenger
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina, USA
    J Clin Psychiatry 65:55-62. 2004
  2. ncbi Remission rates in patients with anxiety disorders treated with paroxetine
    James C Ballenger
    Department of Psychiatry and Behavioral Science, Medical University of South Carolina, Charleston, SC 29401, USA
    J Clin Psychiatry 65:1696-707. 2004
  3. ncbi The use of antiepileptic drugs in bipolar disorders: a review based on evidence from controlled trials
    Richard H Weisler
    University of North Carolina at Chapel Hill, NC, USA
    CNS Spectr 11:788-99. 2006
  4. ncbi A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders
    Mark S George
    Department of Psychiatry, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Brain Stimul 1:112-21. 2008
  5. ncbi Generalized anxiety disorder: comorbidity, comparative biology and treatment
    David J Nutt
    School of Medical Sciences, University of Bristol, UK
    Int J Neuropsychopharmacol 5:315-25. 2002
  6. ncbi Neural correlates of speech anticipatory anxiety in generalized social phobia
    Jeffrey P Lorberbaum
    Department of Psychiatry and Center for Advanced Imaging, Medical University of South Carolina Charleston MUSC, SC 29425, USA
    Neuroreport 15:2701-5. 2004
  7. ncbi Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice
    Robert M Post
    Bipolar Collaborative Network, Chevy Chase, Maryland, USA
    CNS Drugs 21:47-71. 2007

Detail Information

Publications7

  1. ncbi Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety
    James C Ballenger
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina, USA
    J Clin Psychiatry 65:55-62. 2004
    ....
  2. ncbi Remission rates in patients with anxiety disorders treated with paroxetine
    James C Ballenger
    Department of Psychiatry and Behavioral Science, Medical University of South Carolina, Charleston, SC 29401, USA
    J Clin Psychiatry 65:1696-707. 2004
    ..It is proposed that remission is the appropriate target in the treatment of both depression and the anxiety disorders...
  3. ncbi The use of antiepileptic drugs in bipolar disorders: a review based on evidence from controlled trials
    Richard H Weisler
    University of North Carolina at Chapel Hill, NC, USA
    CNS Spectr 11:788-99. 2006
    ..This article provides an overview of data on the use of AEDs in bipolar disorder, including acute mania and depression, prophylaxis, and rapid cycling...
  4. ncbi A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders
    Mark S George
    Department of Psychiatry, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Brain Stimul 1:112-21. 2008
    ....
  5. ncbi Generalized anxiety disorder: comorbidity, comparative biology and treatment
    David J Nutt
    School of Medical Sciences, University of Bristol, UK
    Int J Neuropsychopharmacol 5:315-25. 2002
    ..Finally, current pharmacological and non-pharmacological treatment options for GAD are reviewed, with particular attention being paid to published clinical-trial data...
  6. ncbi Neural correlates of speech anticipatory anxiety in generalized social phobia
    Jeffrey P Lorberbaum
    Department of Psychiatry and Center for Advanced Imaging, Medical University of South Carolina Charleston MUSC, SC 29425, USA
    Neuroreport 15:2701-5. 2004
    ..Phobics may become so anxious, they cannot think clearly or vice versa...
  7. ncbi Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice
    Robert M Post
    Bipolar Collaborative Network, Chevy Chase, Maryland, USA
    CNS Drugs 21:47-71. 2007
    ..More precise clinical and biological predictors and correlates of individual clinical responsiveness to carbamazepine and other mood stabilisers are eagerly awaited...